Want to join the conversation?
Pharma company $SUPN said a sixth patent has been issued by the United States Patent and Trademark Office on May 31 covering Oxtellar XR, a once-daily extended-release oxcarbazepine product. Oxtellar XR is an antiepileptic drug indicated for adjunctive therapy in treating partial seizures in adults and in children 6-17 years of age.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.